AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Genmab A/S
Video analysis: GMAB
All videosNo video analysis for this stock yet. Request one from our team.
News: GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Notice to Convene an Extraordinary General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark. The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached.
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026 :
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript
Genmab A/S Q2 Earnings Call Highlights
Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portfolio. The company also outlined upcoming late-stage trial readouts and announced two new Phase III studies of petosemtamab in colorectal cancer.
Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB
Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company's stock after selling 42,000 shares during the
Similar companies
-
Incyte Corporation
INCY
·
NASDAQ
Compare
-
United Therapeutics Corporation
UTHR
·
NASDAQ
Compare
-
Royalty Pharma plc
RPRX
·
NASDAQ
Compare
-
Tenet Healthcare Corporation
THC
·
New York Stock Exchange
Compare
-
Illumina, Inc.
ILMN
·
NASDAQ
Compare
-
Quest Diagnostics Incorporated
DGX
·
New York Stock Exchange
Compare